Pandion Therapeutics is a clinical-stage biopharmaceutical company that uses a network-based conceptualization of the immune system and advanced protein engineering to develop therapeutics for autoimmune diseases. Their drug design and discovery platform, called TALON, focuses on re-balancing the immune response. Their pipeline includes PT101 for ulcerative colitis and systemic lupus erythematosus, as well as other candidates. Pandion also has PD-1 agonists in development for various autoimmune diseases. Their therapeutic platform is based on bispecific antibodies that target specific tissues at the site of inflammatory disease, coupled with immune modulators to restore immune homeostasis. This localized immunomodulation aims to provide a durable, tissue-specific effect while avoiding systemic immunosuppression.